Brief: Brii Biosciences Announces Topline Interim Results Of Phase 2 Study Evaluating BRII-179 (VBI-2601)
06/09/2023 11:47
Sept 6 (Reuters) - Brii Biosciences Ltd 2137.HK :
* BRII BIOSCIENCES ANNOUNCES TOPLINE INTERIM RESULTS OF
PHASE 2
STUDY EVALUATING BRII-179 (VBI-2601) IN COMBINATION WITH
PEG-IFNΑ FOR THE TREATMENT OF CHRONIC HEPATITIS B
* BRII BIOSCIENCES LTD - SAFETY FINDINGS ARE SIMILAR TO
THOSE OF
PEG-IFNΑ THERAPY AND BRII-179 AS PREVIOUSLY REPORTED
* BRII BIOSCIENCES - INCREASED HBSAG SEROCONVERSION RATE IS
STRONGLY ASSOCIATED WITH BRII-179 TREATMENT AND CORRELATES WITH
INCREASED RATE OF HBSAG LOSS
Source text for Eikon: ID:nPn4gyv9na
Further company coverage: 2137.HK
((Reuters.briefs@thomsonreuters.com;))
Recent news on Brii Biosciences
See all newsBrief: BRII Biosciences Discloses Launch Of BRISC, An SIRNA Therapeutics Discovery Platform
China's Brii Biosciences interim net loss narrows on lower R&D expenses
Brief: Brii Biosciences Announces Share Buy-Back Programme No More Than HK$60 Million
Brief: Brii Biosciences Says Arbitration Between Brii And Vir Remains In Early Stages With No Resolution
Brief: Brii Biosciences Submits Demand For Arbitration Against VIR